← ANALYST RATINGS · TIPRANKS
Gyre Therapeutics (GYRE): analyst forecast and price target
Analyst consensus
Moderate Buy2 Buy0 Hold0 Sell
Ratings of 2 analysts in the last 3 months12-month forecast
Based on 2 price targets given in the last 3 months, the average target is $19.00, the highest $20.00, the lowest $18.00. The average is +212.5% from the last price of $6.08.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $8.00 → $6.50−18.8% | Hold | +6.9% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $8.00 → $6.50−18.8% | Hold | +6.9% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $8.00 → $6.50−18.8% | Hold | +6.9% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $7.50 → $6.00−20.0% | Hold | −1.3% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $8.00 → $6.50−18.8% | Hold | +6.9% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $8.00 → $6.50−18.8% | Hold | +6.9% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| Matthew Keller★★★★★★★★★★#12290 · hits 18% · avg −28.3% | H.C. Wainwright | $18.00 | Buy | +196.1% | Reiterated | 05.10.26on TipRanks 11:30 | +2.7%next day −4.2% · 5 days −7.0% | ↗ |
| Robert LeBoyer★★★★★★★★★★#12335 · hits 27% · avg −14.2% | Noble Financial | $20.00 | Buy | +228.9% | Reiterated | 10.08.26on TipRanks 09:10 | +0.8%next day −0.9% · 5 days +1.4% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Gyre Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $19.00 at a price of $7.33 (+159.2%); now: $19.00 at $6.08 (+212.5%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 2 | 2 | 2 | 2 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 18.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.12 (from $-0.19 to $-0.06). Last quarter: $-0.12.
Sales
Next quarter’s sales estimate — $28M (from $28M to $29M). Last quarter: $29M.
Best top-analyst consensus in the sector · Healthcare
About Gyre Therapeutics
- CEO: Ying Luo
- Employees: 625
- 12770 High Bluff Drive, San Diego, CA, 92130, US
- www.gyretx.com
Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis. Beyond this, ETUARY is also undergoing late-stage (Phase 3) clinical trials for several other conditions, including dermatomyositis and interstitial lung disease linked to systemic sclerosis, pneumoconiosis, and diabetic kidney disease. The company's pipeline further includes F351 (Hydronidone), a compound structurally related to ETUARY. F351 is currently in Phase 3 studies for chronic hepatitis B-induced liver fibrosis and is in Phase 1 trials for liver fibrosis associated with nonalcoholic associated steatohepatitis (NASH). Other programs in development feature F573, which is progressing through Phase 2 studies for acute and acute-on-chronic liver failure. Additionally, two early-stage candidates, F528 and F230, are in preclinical development, focusing on chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH), respectively. Established in 2002, Gyre Therapeutics, Inc. is based in San Diego, California, and operates as a subsidiary of GNI USA, Inc.
Data from the stock’s TipRanks forecast page, read 55 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗